GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Inc (NAS:INBX) » Definitions » PS Ratio

Inhibrx (Inhibrx) PS Ratio : 1,004.71 (As of May. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inhibrx PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Inhibrx's share price is $34.16. Inhibrx's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.03. Hence, Inhibrx's PS Ratio for today is 1,004.71.

The historical rank and industry rank for Inhibrx's PS Ratio or its related term are showing as below:

INBX' s PS Ratio Range Over the Past 10 Years
Min: 38.61   Med: 178.36   Max: 3800
Current: 1002.07

During the past 7 years, Inhibrx's highest PS Ratio was 3800.00. The lowest was 38.61. And the median was 178.36.

INBX's PS Ratio is ranked worse than
96% of 999 companies
in the Biotechnology industry
Industry Median: 9.04 vs INBX: 1002.07

Inhibrx's Revenue per Sharefor the three months ended in Mar. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.03.

Warning Sign:

Inhibrx Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Inhibrx was 9.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -57.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -37.10% per year.

During the past 7 years, Inhibrx's highest 3-Year average Revenue per Share Growth Rate was 22.50% per year. The lowest was -57.80% per year. And the median was -28.40% per year.

Back to Basics: PS Ratio


Inhibrx PS Ratio Historical Data

The historical data trend for Inhibrx's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx PS Ratio Chart

Inhibrx Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - 65.03 233.53 456.30 1,000.00

Inhibrx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 608.71 1,854.29 1,835.00 1,000.00 1,028.24

Competitive Comparison of Inhibrx's PS Ratio

For the Biotechnology subindustry, Inhibrx's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx's PS Ratio distribution charts can be found below:

* The bar in red indicates where Inhibrx's PS Ratio falls into.



Inhibrx PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Inhibrx's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=34.16/0.034
=1,004.71

Inhibrx's Share Price of today is $34.16.
Inhibrx's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Inhibrx  (NAS:INBX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Inhibrx PS Ratio Related Terms

Thank you for viewing the detailed overview of Inhibrx's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx (Inhibrx) Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Executives
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Mark Lappe director, 10 percent owner, officer: Chief Executive Officer 11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Brendan P. Eckelman director, 10 percent owner, officer: Chief Scientific Officer C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jon Faiz Kayyem director, 10 percent owner 5964 LA PLACE COURT, CARLSBAD CA 92008
Dragsa 50 Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Klaus W. Wagner officer: Chief Medical Officer C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121

Inhibrx (Inhibrx) Headlines